RECURRENT WHO GRADE III GLIOMA
Clinical trials for RECURRENT WHO GRADE III GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE III GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE III GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune therapy targets deadliest brain tumors
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy (CAR T cells) designed to target and kill glioblastoma, an aggressive brain cancer that has returned or worsened. The therapy uses a special targeting domain (chlorotoxin) to seek out cancer cells. The study involves …
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
New hope for young brain tumor patients: drug duo targets hard-to-treat gliomas
Disease control OngoingThis early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnosed o…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Genetically modified stem cells target recurrent brain cancer
Disease control OngoingThis early-phase trial tests a new approach for people with high-grade gliomas that have returned after prior treatment. Genetically modified neural stem cells are placed directly into the brain tumor to make it more sensitive to the chemotherapy drug irinotecan. The main goal is…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control OngoingThis early-phase study tests a new immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a gene that helps them recognize and attack glioma cells, and infuse t…
Matched conditions: RECURRENT WHO GRADE III GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC